处方药市场：现状分析与预测（2022-2028）

全球范围内心血管疾病、高血压和糖尿病等慢性病患病率的不断上升正在推动处方药市场的增长。 例如，疾病控制中心在2022 年报告称，生活在美国的大约2,010 万名成年人(7.2%) 患有某种形式的冠状动脉疾病(CAD)，根据上面列出的来源，大约805,000 名生活在美国的成年人患有某种形式的冠状动脉疾病(CAD)。美国会心脏病发作，其中605,000人会首次心脏病发作，200,000人以前有过心脏病发作，大约五分之一的心脏病发作是无声的发作。 此外，用于治疗 CAD 的药物要么是短期服用，要么是终生服用。 此外，如果没有获得许可的医疗保健专业人员的书面指示，则无法获得这些药物。 因此，全球慢性病患病率的不断上升预计将在预测期内推动处方药市场的增长。

根据产品类型，市场分为仿製药、品牌药、孤儿药等。 其中，仿製药领域预计2021年市场复合年增长率较大。 这是由于原研药的专利到期和随后的监管批准。 与品牌药相比，仿製药的生产成本相对较低。 这使仿製药公司有机会为消费者提供负担得起的替代品。

市场按治疗领域分为癌症、抗糖尿病、疫苗、感觉器官、免疫抑製剂、抗凝剂等。 其中，预计2021年免疫抑製剂领域的市场复合年增长率将大幅增长。 这是由于自身免疫性疾病的患病率不断增加以及全球器官移植手术数量的增加。

根据分销渠道，市场分为医院药房、零售药房和网上药房。 其中，预计酒店药房市场在预测期内将以显着的复合年增长率增长。 这是因为患者更喜欢从医院购买药品。 此外，服务态度好的医院药房购买药品也可靠、安全，不会购买来源不可靠的假冒品牌药品。 此外，住院患者从医院购买药品也很方便。 因此，上述因素预计将推动该领域的市场增长。

为了更好地了解处方药行业的市场介绍，市场有北美（美国、加拿大、北美其他地区）、欧洲（英国、德国、法国、意大利、西班牙、欧洲其他地区）、亚洲太平洋地区（中国、日本、印度、韩国等亚太地区）以及世界其他地区。 预计亚太地区在预测期内将以显着的复合年增长率增长。 这主要是由于该地区仿製药製造商的增加、慢性病患病率的上升以及医疗保健支出的增加，所有这些都推动了处方药的需求。

目录

第一章市场介绍

• 市场定义
• 主要目的
• 利益相关者
• 限制

第二章研究方法或假设

• 调查过程
• 调查方法
• 受访者简介

第三章市场总结

第 4 章执行摘要

第五章新型冠状病毒感染（COVID-19）对全球处方药市场的影响

第 6 章 2020-2028 年全球处方药市场收入

第 7 章按产品类型划分的市场洞察

• 通用
• 孤儿
• 其他

第 8 章按治疗领域划分的市场洞察

• 肿瘤学
• 抗糖尿病药物
• 疫苗
• 感觉器官
• 免疫抑製剂
• 抗凝剂
• 其他

第 9 章按分销渠道划分的市场洞察

• 医院药房
• 零售药店
• 网上药店

第 10 章按地区划分的市场洞察

• 北美市场
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲市场
  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲地区
• 亚太市场
  • 中国
  • 日本
  • 印度
  • 韩国
  • 亚太地区的其他国家/地区
• 世界其他地区的市场

第11章处方药市场动态

• 市场驱动因素
• 市场挑战
• 影响分析

第 12 章处方药市场机会

第13章处方药市场趋势

第14章需求侧和供给侧分析

• 需求方分析
• 供给侧分析

第 15 章战略洞察

第16章竞争场景

• 竞争状况
  • 波特五力分析

第17章公司简介

• F. Hoffmann-La Roche Ltd
• Teva Pharmaceuticals USA, Inc.
• sanofi-aventis U.S. LLC
• Pfizer Inc.
• GSK plc
• Novartis AG
• Merck & Co., Inc.,
• AbbVie Inc.
• AstraZeneca
• Johnson & Johnson Services, Inc.

第18章 免责事项

Prescription Drugs are the types of medication that can only be available to the patient only against the written instruction from the licenced healthcare professional. It includes information about the medication, how to be consumed, duration of treatment and frequency of the medication to be taken.

The increase in the prevalence of chronic diseases such as cardiovascular diseases, hypertension and diabetes across the globe is driving the market growth of prescription medicine. For instance, the Centre for disease control 2022, reports, around 20.1 (7.2%) million adults living in the United States have some type of coronary artery disease (CAD), further as per the above-mentioned source approximately 805,000 people living in the United States have heart attacks, of these 605,000 have a first heart attack, 200,000 are those people who already have had a heart attack and about 1 in 5 heart attack are silent ie, the damage is done and the person is unaware. Additionally, the medication taken for the treatment of CAD is either consumed for a short duration or lifelong. Furthermore, these medications are only be obtained against written instruction from a licenced healthcare professional. Hence, the growing prevalence of chronic disease across the globe is anticipated to boost market growth for prescription medicine in the forecasted period.

Based on product type, the market is segmented into generics, branded, orphans and others. Amongst these, the generic drug segment is anticipated to grow with a significant CAGR in the 2021 market. This is attributed to the patent expiration of the branded drugs coupled with their subsequent approval by the regulatory authority. Generic drugs are produced comparatively at low cost contrary to branded drugs. This creates an opportunity for generic companies to offer affordable alternatives to consumers.

Based on the therapeutic area the market is segmented into oncology, anti-diabetic, vaccines, sensory organs, immunosuppressants, anti-coagulants and others. Amongst these, the immunosuppressant segment is anticipated to grow with a significant CAGR in the 2021 market. This is attributed to the growing prevalence of autoimmune diseases and the rise in organ transplantation procedures globally. For instance according to the Global Observatory Donation and Transplant (GODT) report, 2021 the no. of organs transplanted increased from 1,44,302 in 2021 to 1,29,680 in 2020. This accounted for 11.3% in 2021 from 2020. Additionally, these medication helps to suppress the immunity and further prevents the organ rejection response of the body. Thus, with the rising prevalence of autoimmune diseases and increase in incidences of organ transplantation procedure is driving the market growth during the forecasted period.

Based on the distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Amongst these the hospital pharmacies segment is anticipated to grow with a significant CAGR during the forecasted period. This is due to patients' preference for purchasing medicine from hospitals. Furthermore, hospital pharmacy source is reliable and safe for drug purchase, as it eliminates the purchase of misbranded drug purchased from non-reliable sources. Moreover, for inpatients, purchasing drugs from hospital pharmacies is easily accessible. Thus, the above-mentioned factors are anticipated to ful the market growth of this segment.

For a better understanding of the market adoption of the Prescription Drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is primarily driven by the increase in generic drug manufacturers, rising prevalence of chronic diseases and the increase in healthcare expenditure in this region is propelling the demand for prescription drugs.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals USA, Inc., Sanofi-aventis U.S. LLC, Pfizer Inc., GSK plc, Novartis AG, Merck & Co., Inc., AbbVie Inc. , AstraZeneca, Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Prescription Drugs Market
• 2.2. Research Methodology of the Prescription Drugs Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL PRESCRIPTION DRUGS MARKET COVID-19 IMPACT

6 GLOBAL PRESCRIPTION DRUGS MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Generic
• 7.2. Orphan
• 7.3. Others

8 MARKET INSIGHTS BY THERAPEUTIC AREA

• 8.1. Oncology
• 8.2. Anti-Diabetic
• 8.3. Vaccines
• 8.4. Sensory Organs
• 8.5. Immunosuppressant's
• 8.6. Anti-Coagulant
• 8.7. Others

9 MARKET INSIGHT BY DISTRIBUTION CHANNEL

• 9.1 Hospital Pharmacies
• 9.2 Retail Pharmacies
• 9.3 Online Pharmacies

10 MARKET INSIGHTS BY REGION

• 10.1 North America Market
  • 10.1.1 U.S.
  • 10.1.2 Canada
  • 10.1.3 Rest of North America
• 10.2 Europe Market
  • 10.2.1 UK
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific Market
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Rest of APAC
• 10.4 Rest of the World Market

11 Prescription drugs MARKET DYNAMICS

• 11.1 Market Drivers
• 11.2 Market Challenges
• 11.3 Impact Analysis

12 PRESCRIPTION DRUGS MARKET OPPORTUNITIES

13 PRESCRIPTION DRUGS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1 Demand Side Analysis
• 14.2 Supply Side Analysis

15 STRATEGIC INSIGHTS

16 COMPETITIVE SCENARIO

• 16.1 Competitive Landscape
  • 16.1.1 Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 F. Hoffmann-La Roche Ltd
• 17.2 Teva Pharmaceuticals USA, Inc.
• 17.3 sanofi-aventis U.S. LLC
• 17.4 Pfizer Inc.
• 17.5 GSK plc
• 17.6 Novartis AG
• 17.7 Merck & Co., Inc.,
• 17.8 AbbVie Inc.
• 17.9 AstraZeneca
• 17.10. Johnson & Johnson Services, Inc.

17 DISCLAIMER